Add-on clinical effects of selective antagonist of 5HT6 receptors AVN-211 (CD-008-0173) in patients with schizophrenia stabilized on antipsychotic treatment: pilot study

@article{Morozova2013AddonCE,
  title={Add-on clinical effects of selective antagonist of 5HT6 receptors AVN-211 (CD-008-0173) in patients with schizophrenia stabilized on antipsychotic treatment: pilot study},
  author={Margarita A. Morozova and T A Lepilkina and G E Rupchev and Allan G. Beniashvily and D S Burminskiy and Sergey S. Potanin and Evgeny V Bondarenko and V. I. Kazey and Yan Lavrovsky and Alexandre V Ivachtchenko},
  journal={CNS Spectrums},
  year={2013},
  volume={19},
  pages={316 - 323}
}
The serotoninergic system as a target for add-on treatment seems to be a promising approach in patients with schizophrenia. Objective To clarify if selective 5HT-6 antagonist AVN-211 (CD-008-0173) adds clinical and cognitive effects to stable antipsychotic treatment. Methods A randomized, double-blind, placebo-controlled, add-on, 4r-week trial in 47 schizophrenia patients (21 patients receiving study drug and 26 receiving placebo) who were stabilized on antipsychotic medication was performed… 

5-HT6 Receptor Antagonist as an Adjunct Treatment Targeting Residual Symptoms in Patients With Schizophrenia: Unexpected Sex-Related Effects (Double-Blind Placebo-Controlled Trial)

It is suggested that the role of patients' sex can impact the treatment response to serotonergic drugs in general and a possible synergistic interaction between estrogen and Avisetron by means of modulating the effect of estrogens on theserotonergic system is suggested.

Potential serotonergic agents for the treatment of schizophrenia

The authors describe the recent clinical trials for schizophrenia with selective serotonergic agents and provide an opinion on how the investigated drugs can help to fulfil current treatment needs.

Experimental Serotonergic Agents for the Treatment of Schizophrenia

Although some serotonergic drugs seem promising for improving the treatment of schizophrenia, further studies regarding the pathophysiological mechanisms of schizophrenia and novel compounds as well as high-quality trials are necessary in order to improve schizophrenia outcomes.

Efficacy of different types of cognitive enhancers for patients with schizophrenia: a meta-analysis

Overall, this meta-analysis showed few favorable effects of cognitive enhancers for patients with schizophrenia, partly due to lack of power.

AVN-211, Novel and Highly Selective 5-HT6 Receptor Small Molecule Antagonist, for the Treatment of Alzheimer's Disease.

AVN-211 significantly delayed or partially halted the progressive decline in memory function associated with AD, which makes it an interesting drug candidate for the treatment of neurodegenerative and psychiatric disorders.

AVN-492, A Novel Highly Selective 5-HT6R Antagonist: Preclinical Evaluation.

The data presented here strongly indicate that AVN-492 is a very promising tool for evaluating the role the 5-HT6 receptor might play in cognitive and neurodegenerative impairments, and is an excellent drug candidate to be tested for treatment of such diseases.

Ef fi cacy of different types of cognitive enhancers for patients with schizophrenia : a meta-analysis

Overall, this meta-analysis showed few favorable effects of cognitive enhancers for patients with schizophrenia, partly due to lack of power.

Serotonin Type 6 and 7 Receptors as a Novel Therapeutic Target for the Treatment of Schizophrenia

Research on novel drugs that act on serotonin 6 and 7 receptors likely facilitates the intervention into schizophrenia patients seeking better quality of life in the future.

References

SHOWING 1-10 OF 76 REFERENCES

Double-blind placebo-controlled randomized efficacy and safety trial of add-on treatment of dimebon plus risperidone in schizophrenic patients during transition from acute psychotic episode to remission.

Dimebon as add-on therapy to antipsychotic treatment in the period of stabilization after an acute episode can improve some aspects of clinical and cognitive status in schizophrenic patients.

Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial.

Combining aripiprazole and clozapine resulted in significant weight, BMI and fasting cholesterol benefits to patients suboptimally treated with clozAPine and there were no significant differences in Positive and Negative Syndrome Scale total score changes between groups.

A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia.

An adequately powered randomized controlled trial adding d-serine, an NMDA modulator, to antipsychotics, which did not find a significant difference between drug and placebo.

[Effects of the anticholinesterase drug neuromidin in patients with schizophrenia with marked neurocognitive deficits].

The authors conclude that the problem of rationality of add-on anticholinergic treatment in schizophrenia is not solved yet due to the difficulties in selection of patients and tests for cognitive assessment.

Role of the cholinesterase inhibitors in the treatment of schizophrenia

  • C. Pae
  • Psychology, Medicine
    Expert opinion on investigational drugs
  • 2013
Cholinesterase inhibitors (ChEIs) may be effective in enhancing the cognitive functioning of patients with schizophrenia and are considered potential therapeutic targets for new drugs designed to decrease cognitive deficits.

Serotonin receptors as targets for drugs useful to treat psychosis and cognitive impairment in schizophrenia.

Preclinical evidence is reviewed to support the importance of 5-HT2A receptor inverse agonism to the action of clozapine and related atypical APDs, and evidence supporting the potential of selective 4-HT1A partial agonists and 5- HT2C agonists for development of drugs which ameliorate psychosis or cognitive impairment.

Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.

After 2 months of antipsychotic treatment, all groups had a small but significant improvement in neurocognition, and after 18 months of treatment, neurocognitive improvement was greater in the perphenazine group than in the olanzapine and risperidone groups.

Muscarinic mechanisms in psychotic disorders.

It is proposed that an agonist with M(1) and M(4) interactions would effectively treat core symptom clusters associated with schizophrenia.
...